PubRank

Expression of hepatocyte growth factor and c-Met is characteristic of α-fetoprotein-producing colorectal adenocarcinoma: A report of three cases.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26870275)

Published in Oncol Lett on November 24, 2015

Authors

Jun Li1, Yue Liu2, Jing-Hong Xu3, Zheng-Ping Xu4, Shu Zheng1, Ke-Feng Ding1

Author Affiliations

1: Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China; Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, Zhejiang 310009, P.R. China.
2: Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, Zhejiang 310009, P.R. China.
3: Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education, Hangzhou, Zhejiang 310009, P.R. China; Department of Pathology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China.
4: Department of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China.

Articles cited by this ↗

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73

An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report. Cancer (1985) 2.72

Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis. Cancer (1993) 2.29

Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20

Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol (2013) 1.70

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res (2010) 1.50

Clinicopathologic characteristics and treatment outcomes of hepatoid adenocarcinoma of the stomach, a rare but unique subtype of gastric cancer. BMC Gastroenterol (2011) 1.20

Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit Rev Oncol Hematol (2013) 0.93